Effect of Unani Formulations in Migraine headache
- Conditions
- Health Condition 1: G00-G99- Diseases of the nervous system
- Registration Number
- CTRI/2023/05/052944
- Lead Sponsor
- ational Institute of Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Diagnosed cases of Migraine without Aura (as per the International Classification of Headache Disorders (ICHD-3) with history for at least one year
2.Patients between the age of 18â??50 years
3.Patients of any gender
4. Patients who will give consent and are able to do follow up
1.Headache other than Migraine without Aura
2.Use of any migraine prophylactic agents (b-blockers, anti-depressants, calcium channel blockers, anti-epileptic agents, cycle-modulating hormonal drugs, or vessel dilatation agents) within 1 month prior to screen
3.History or evidence of psychiatric disorder
4.Patients with a score of 19 or higher on the Beck Depression Inventory-II (BDI-II)
5.History of any systemic illness
6.Pregnant and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 50% Reduction in Monthly Migraine Days (MMD) <br/ ><br> <br/ ><br>Timepoint: 0th, 30th and 60th day <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method oReduction in the Headache Impact Test (HIT-6) <br/ ><br>oIncrease in the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQv2.1) <br/ ><br>Timepoint: 0th, 30th and 60th day